Does hospital overload increase the risk of death when infected by SARS-CoV-2?

Benjamin Glemain^{1,2*}, Charles Assaad¹, Walid Ghosn³,

Paul Moulaire¹, Xavier de Lamballerie⁴, Marie Zins^{5,6},

Gianluca Severi^{7,8}, Mathilde Touvier⁹, Jean-François Deleuze¹⁰,

SAPRIS-SERO study group, Nathanaël Lapidus^{$1,2^{\dagger}$},

Fabrice Carrat^{1,2†}

¹Sorbonne Université, Inserm, Institut Pierre-Louis d'épidémiologie et de santé publique, Paris, France.

²Département de santé publique, Hôpital Saint-Antoine, APHP, Paris, France.

³Centre d'épidémiologie sur les causes médicales de décès de l'Inserm, Inserm-CépiDc, Paris, France.

⁴Unité des Virus Émergents, UVE, Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, Marseille, France.

⁵Paris University, Paris, France.

⁶Université Paris-Saclay, Université de Paris, UVSQ, Inserm UMS 11, Villejuif, France.

⁷CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France.

⁸Department of Statistics, Computer Science and Applications, University of Florence, Italy.

⁹Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam,

Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center – University of Paris (CRESS), Bobigny,

France.

¹⁰Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France.

*Corresponding author(s). E-mail(s): benjamin.glemain@inserm.fr; †These authors contributed equally to this work.

1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Several studies found an association between the risk of death for COVID-19 patients and hospital overload during the first pandemic wave. We studied this association across the French departments using 82,467 serological samples and a hierarchical Bayesian model. In high-incidence areas, we hypothesized that hospital overload would increase infection fatality rate (IFR) without increasing infection hospitalization rate (IHR). We found that increasing departmental incidence from 3% to 9% rose IFR from 0.42% to 1.14%, and IHR from 1.66% to 3.61%. An increase in incidence from 6% to 12% in people under 60 was associated with an increase in the proportion of people over 60 among those infected, from 11.6% to 17.4%. Higher incidence did increase the risk of death for infected persons, probably due to an older infected population in high-incidence areas rather than hospital overload.

Keywords: COVID-19, Hospital overload, Bayesian statistics, Hierarchical modeling, Spatial modeling, Causal graph

1 Introduction

The first wave of the COVID-19 pandemic led to episodes of hospital overload in many 2 parts of the world, requiring the urgent provision of additional hospital beds to pre-3 vent excess mortality [1, 2]. Temporary units were set up, but suspected of being less effective than permanent units (although these comparisons were impeded by con-5 founders such as admission criteria) [3–5]. Indeed, hospital overload can manifest in 6 several ways. First, it can appear as a lack of hospital bed availability, resulting in a lower proportion of infected individuals being hospitalized. Second, it can lead to a decrease in the quality of care due to the urgent addition of extra beds with potentially inadequate facilities, equipment, or staff. Hospital overload thus has multiple 10 aspects, making it difficult to measure using a single indicator. 11

So far, the consequences of these episodes of hospital overload on the risk of death for 12

- infected persons have mainly been studied through the number of confirmed COVID-13 19 cases, using the case fatality rate (CFR) [6-8]. Hospital overload was notably 14 expressed as the ratio between the number of COVID-19 cases and baseline hospital 15 resources, a measure that does not distinguish between situations of high incidence 16
- and those of insufficient hospital resources at baseline [6]. In addition, CFR analysis is 17
- limited by spatial and temporal variations in the case detection rate (the proportion 18 of new cases that are detected) [9, 10]. 19
- To overcome the limitations of the cases-based approach, several studies used serolog-20
- ical data and estimated infection fatality rates (IFRs) [11-14]. IFR is defined as the 21
- number of deaths attributed to COVID-19 during a given period divided by the num-22
- ber of infected individuals (incidence) over the same period, and corresponds to the 23
- risk of death for infected persons. These studies compared IFRs across countries and 24
- age groups, but did not explore the impact of hospital overload. 25
- Built on the seroprevalence study SAPRIS-SERO, the present work aimed to estimate

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

27 the effect of COVID-19 incidence on IFR at the scale of the metropolitan depart-

²⁸ ments of France during the first pandemic wave in the population over 20. We used a

²⁹ Bayesian statistical framework to leverage multiple sources of data and to account for

³⁰ uncertainty surrounding the latent variables when used in regressions (such as inci-³¹ dence and IFR). As incidence (understood as a cumulative incidence over the first

dence and IFR). As incidence (understood as a cumulative incidence over the first wave) was reported to range from 3% to 9% in the French regions (administrative sub-

divisions gathering several departments), the consequences of an incidence shift from

 $_{34}$ 3% to 9% on IFR were the main object of this study [15, 16].

 $_{\tt 35}$ $\,$ The relation between incidence and IFR is however confounded, notably because the

determinants of IFR may share socio-economic causes with incidence at the scale of

departments. Typically, wealthier departments could have a population which travels more (possibly increasing incidence) and which is healthier (decreasing IFR), partici-

pating in a spurious negative association between incidence and IFR. Thus, IFR was

⁴⁰ adjusted (by conditioning and averaging, as described in the Methods section) for the

 $_{41}$ main determinants of COVID-19 outcome: prevalence of diabetes (as a surrogate for

⁴² obesity), proportion of the population over 60, and number of intensive care beds per

 $_{43}$ inhabitant (see the dedicated subsection: Choice of the covariates) [6, 7, 17, 18]. In

the Methods section (equation 15), we formalize the equivalence between (i) the association between incidence and adjusted IFR and (ii) the causal effect of incidence on

⁴⁵ clation between incidence and adjusted IFR and (ii) the causal effect

⁴⁶ IFR, using the structural causal models framework.

⁴⁷ Finally, the mechanisms by which incidence could influence IFR were explored. Evi-

dence for hospital overload with shortage of hospital beds was sought by examining 48 the effect of COVID-19 incidence on infection hospitalization rate (IHR), which is the 49 proportion of infected individuals being hospitalized for COVID-19. The age of the 50 infected individuals may also play a role in the effect of incidence on IFR. Indeed, it 51 52 has been suggested that older persons could be under-represented in the population of infected people at the early stages of the epidemic [19]. To determine if infected 53 individuals were actually younger in departments with low incidence, the dependence 54 between COVID-19 incidence in people under 60 and the proportion of individuals 55 over 60 among those infected was investigated. 56

57 2 Results

58 2.1 Participants

The study included 82,467 persons with a serological test, living in metropolitan 59 France, and over 20 years old. All serological samples were collected between May and 60 November 2020. Among the participants, 319 reported a positive RT-PCR. These lat-61 ter had a mean age of 52 years, 29% of them were males, and the median time elapsed 62 between RT-PCR and dried blood sampling was 111 days (IQR: 68-128). The partic-63 ipants with a positive RT-PCR were considered infected. On the other hand, 82,148 64 participants reported no positive RT-PCR (no RT-PCR or a negative RT-PCR). These 65 participants had a mean age of 58 years, and 35% of them were males. A detailed 66 flowchart and a table with the number of samples for each department and age group 67 are provided in the Supplementary information file. 68

2.2 Departmental incidence, IFR, and IHR

The model estimated an incidence of 6.8% over the first wave in metropolitan France, 70 with a 95% credible interval (95% CI) of 6.4 to 7.2%. Figure 1 displays a map of



Fig. 1: COVID-19 departmental incidence (cumulated over the first wave) in metropolitan France.

departmental incidence, showing that north-east France was the most affected area. 72

Indeed, departmental incidence ranged from 2.5% (95% CI: 1.8-3.4%), in Ariège (a 73

south-west department), to 13.6% (95% CI: 12.1-15.2%), in Haut-Rhin (a north-east 74 department). 75

The overall infection fatality rate in metropolitan France was 0.94% (95% CI: 0.89-76 0.99%) and infection hospitalization rate was 3.28% (95% CI: 3.10-3.46%). IFR ranged 77

from 0.27% (95% CI: 0.21-0.33%), in Haute-Garonne (a south-west department with 78

- low COVID-19 incidence), to 1.97% (95% CI: 1.74-2.22%), in Haut-Rhin (the depart-79
- ment with the highest COVID-19 incidence, located in the north-east of france). IHR 80 ranged from 1.02% (95% CI: 0.72-1.42%), in Tarn-et-Garonne, to 5.92% (95% CI:

81 5.09-6.79%), in Territoire de Belfort. The Supplementary information file provides 82

exhaustive departmental estimates (incidence, IFR, IHR). 83

2.3 Effect of incidence on IFR and IHR 84

71

Figure 2 illustrates the association between departmental incidence and adjusted IFR, 85

or adjusted IHR (adjustment for the proportion of persons over 60 in the population, 86

for the prevalence of diabetes, and for the number of intensive care beds per inhab-87

itant). An incidence of 3% was associated with an adjusted IFR of 0.42% (95% CI: 88

- 0.33-0.52%), and an incidence of 9% was associated with an adjusted IFR of 1.14%89
- (95% CI: 0.95-1.39%). The absolute difference (equivalent to the average causal effect







Fig. 2: Effect of departmental incidence on infection fatality rate (IFR) and on infection hospitalization rate (IHR).

The points represent the mean posterior departmental estimates.

Black line and gray zone: Posterior mean and 95% CI of the expected adjusted departmental IFR given incidence (or expected causal effect of incidence on IFR: see equation 15 of the Methods). The same description applies to IHR.

The covariates are represented relative to their medians.

Pop. over 60: Proportion of adult population over 60.

ICU beds per 1,000 inhab.: Number of intensive care beds per 1,000 inhabitants.

of an incidence shift from 3% to 9%) was 0.72% (95% CI: 0.49-1.01%). 91

An incidence of 3% was associated with an adjusted IHR of 1.66% (95% CI: 1.30-92

2.06%), and an incidence of 9% was associated with an adjusted IHR of 3.61% (95% CI: 93

3.05-4.28%). The absolute difference was 1.94% (95% CI: 1.18-2.80%). 94

Complementary results (univariate analysis, role of the confounders) are provided in 95

the Supplementary information file. 96

2.4 Association between incidence and age of infected persons 97

As illustrated in Figure 3, a shift in incidence in the persons under 60 from 6% to 12%98

(typical observed values) was associated with an increase in the expected proportion of 99

persons over 60 among those infected for a department with the same age structure as 100

metropolitan France, from 11.6% (95% CI: 9.6-13.6%) to 17.4% (95% CI: 15.5-19.5%). 101

The absolute difference was 5.8% (95% CI: 2.9-8.8%). 102



Fig. 3: Association between incidence in people under 60 and the proportion of people over 60 among those infected.

The points represent the mean posterior departmental estimates.

Black line and gray zone: Posterior mean and 95% CI of the expected proportion of persons over 60 among those infected (for a department with the same age structure as metropolitan France).

3 Discussion 103

This study explored the role of hospital overload on the risk of death for COVID-19 104 patients (IFR) using data collected in France following the first pandemic wave. We 105 found that a higher departmental incidence was associated with a higher adjusted 106 IFR, corresponding to a causal effect of incidence on IFR. This effect could possibly 107 be explained by the age of the infected persons, as we found a higher proportion of 108 people aged over 60 among those infected in high-incidence departments. The role of 109 hospital overload was explored through the analysis of the probability of hospitaliza-110 tion when infected (IHR). In case of hospital overload with a lack of beds, we would 111 have expected a decrease in the proportion of infected individuals who are hospitalized. 112 In case of hospital overload with sufficient additional beds available but a decrease 113 in the quality of care, we would have expected IHR to remain stable with incidence 114 (since infected individuals could have been hospitalized without restriction). On the 115 contrary, we found that an incidence shift from 3% to 9% increased IHR by the same 116 magnitude as IFR (by a factor of two to three), consistent with the increase in the age 117 of infected individuals with incidence (since both IHR and IFR increase with age) [20]. 118 Previous studies have compared IFR between countries and have found that age-119 specific IFR was the main predictor of country-level IFR [11]. However, IFR varied 120 strongly between countries (by a factor of more than 30 in [11]), even after account-121 ing for the age of the infected individuals [13, 14]. In particular, European countries 122 faced higher IFRs than expected [11-13], suggesting the importance of other determi-123 nants of IFR than age and health-care capacity [11]. Focusing on a single country was 124

 $\mathbf{6}$

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

a first strength of our study, as it eliminated the influence of any country-level con-125 founder (heterogeneity in populations, healthcare systems, mitigation policies, etc.), 126 by design. Furthermore, the association between departmental incidence and IFR was 127 not explained by the covariates we used: baseline hospital resources (measured as the 128 number of intensive care beds per inhabitant), proportion of the population over 60, 129 or prevalence of diabetes (used as a proxy for obesity). This association between inci-130 dence and adjusted IFR was also suggested in one international comparison (see the 131 Figure 3 of |14|). 132

Some other studies found a positive association between a higher case fatality rate 133 (CFR) and hospital overload in the US and in France [4, 6]. In these studies, hospital 134 overload was measured either by the number of hospitalizations for COVID-19 or by 135 the ratio between COVID-19 cases and hospital resources, such as ICU beds or nurs-136 ing staff. In one of these studies, CFR was standardized for the age of the population, 137 but not for the age of the infected individuals [4]. These findings may be explained 138 by the role of incidence. Indeed, hospital overload increases with incidence, as does 139 the age of infected individuals (and consequently, IFR). Incidence could therefore be 140 a confounder for hospital overload and IFR. 141

An important strength of this study was the Bayesian statistical framework, which 142 accounted for uncertainty in the latent variables used in the regressions (such as inci-143 dence or IFR). Indeed, underestimation of incidence results in overestimation of IFR 144 (since the number of COVID-19 related deaths is known), and overestimation of inci-145 dence leads to underestimation of IFR. Thus, sampling variation contributes to a 146 spurious negative association between incidence and IFR, as evidenced in the pos-147 terior predictive checks (see the Supplementary information file). Considering these 148 latent variables as known during the regression step would therefore have led to biased 149 results. 150

A limitation of our study was that focusing on a single country could reduce exter-151 nal validity, particularly for countries on other continents or with different levels of 152 development. A second limitation relates to the causal assumptions we have made, 153 as they result in a simplified view of the relation between the variables. We used the 154 prevalence of diabetes as a surrogate for obesity because it is easier to collect data on 155 (through diabetes medication), and not all risk factors for COVID-19 death were con-156 sidered (like immunosuppression). However, these assumptions enabled formal causal 157 reasoning using graphs, which is not vet widely practiced in health research [21]. This 158 formalism contributes to greater clarity regarding the questions asked and the mech-159 anisms under study. 160

In conclusion, this study found that a higher incidence increased the risk of death 161 among individuals infected with COVID-19. However, the mechanism of this effect 162 could be related to a shift in the profile of infected individuals with incidence. Indeed, 163 the departments with lower incidence tended to have a younger infected population (to 164 be distinguished from the age of the general population of the department). These find-165 ings prompt a reinterpretation of studies that have observed an association between 166 the number of COVID-19 cases in a specific location and the risk of death among 167 infected individuals, as the age of infected persons was generally not considered. It is 168

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

¹⁶⁹ important to emphasize that while we did not find epidemiological evidence implicat-

¹⁷⁰ ing hospital overload in increasing the risk of death among COVID-19 patients, this

¹⁷¹ does not negate the possibility of such an effect.

172 4 Methods

173 4.1 SAPRIS-SERO study

This study used the data of the SAPRIS-SERO serosurvey, previously described [16, 22, 23]. SAPRIS-SERO was built on SAPRIS ("SAnté, Perception, pratiques, Relations et Inégalités Sociales en population générale pendant la crise COVID-19"), a cohort whose inclusions began in March 2020, which studied epidemiological and sociological aspects of the COVID-19 epidemic in France [22]. The adult participants of SAPRIS were recruited from three cohorts based on the general population (without particular selection on a disease):

- The cohort NutriNet-Santé focused on nutrition, with online follow-up. It included
 170,000 participants at the start of the study in 2009 [24].
- The cohort CONSTANCES was set up in 2012 and included 204,973 adults, selected to be a representative sample of the French adult population [25].
- E3N/E4N is a multi-generational adult cohort including 113,000 persons: the
- women recruited at the start of the study (1990), their children, and the fathers of these children [26].

All participants from the initial cohorts who had regular internet access and were still 188 being followed in 2020 were invited to participate in the SAPRIS study, which involved 189 self-administered questionnaires during the first wave. These questionnaires covered 190 demographic information and the history of SARS-CoV-2 testing by RT-PCR. A total 191 of 93,610 SAPRIS participants were over 20, completed the questionnaires, and resided 192 in metropolitan France. These participants were then invited to join the SAPRIS-193 SERO study by collecting a single dried-blood spot sample themselves. The samples 194 were sent to a virology laboratory (Unité des virus émergents, Marseille, France) for 195 serological analysis using the commercial ELISA test (Euroimmun, Lübeck, Germany), 196 which detects anti-SARS-CoV-2 IgG antibodies targeting the S1 domain of the spike 197 protein. The ELISA assays performed on dried-blood spot samples demonstrated a 198 sensitivity of 98.1% to 100% and a specificity of 99.3% to 100% when compared to 199 conventional serum assays as a standard [27, 28]. 200

201 4.2 External data

The results of two independent French seroprevalence studies were used as prior distributions for national seroprevalence (metropolitan France) [15, 29]. The results of a diagnostic study concerning the ELISA test (IgG anti-S1 from Euroimmun) were used as prior distributions for sensitivity and specificity [30].

 $_{\rm 206}$ $\,$ The French population structure by age and by administrative department came from

the census of January first, 2020 (Insee, Institut national de la statistique et des études économiques) [31]. The data about COVID-19-related hospitalizations during the first

²⁰⁹ semester (before July first, 2020) by administrative department were obtained from

the SI-VIC database, the exhaustive national inpatient surveillance system used dur-210 ing the pandemic [32]. The data about general population mortality (including deaths 211 occurring in nursing homes) attributed to COVID-19 during the first semester (before 212 July first, 2020) were obtained from the CépiDc (Centre d'épidémiologie sur les causes 213 médicales de décès), online (open data) or directly [33]. Raw diabetes prevalence in 214 French departments in 2019 (pre-pandemic) was provided by Santé Publique France 215 (open data), based on an exhaustive monitoring of anti-diabetic drugs use (Système 216 national des données de santé) [34]. The number of ICU (intensive care unit) beds 217 per inhabitant in 2019 (pre-pandemic) was obtained from the DREES (Direction de 218 la recherche, des études, de l'évaluation et des statistiques) [35]. 219

4.3 Choice of the covariates 220

Figure 4 features a causal graph representing departmental incidence (X), IFR or



Fig. 4: Causal graph. The variables are considered at the departmental scale. The effect of X on Y can be estimated by adjusting on $\{Diab., Age, Beds\}$.

X: COVID-19 incidence.

Y: IFR (infection fatality rate) or IHR (infection hospitalization rate).

Diab.: Prevalence of diabetes.

Beds: Number of intensive care beds per inhabitant.

Age: Proportion of population over 60.

Dashed arrows represent the effects of unmeasured confounders C.

221

IHR (Y), unobserved socio-economic variables (C), and the determinants of COVID-222 19 outcome (according to [6, 7, 17, 18]). Our most critical assumptions, which are 223 included in the graph, are: 224

Age and diabetes are the main individual risk factors for COVID-19 severity, 225 influencing hospitalization and mortality. 226

The determinants of IFR and IHR at the departmental scale act through the 227 prevalence of these individual risk factors, through incidence, or through the 228 number of intensive care beds per inhabitant (the latter having a potentially 229 decisive role for IFR but acting as a surrogate for hospital beds when considering 230 IHR). 231

Given this causal graph (Figure 4), the set {Diab., Age, Beds} satisfies the back-232 door criterion relative to (X, Y) and allows for estimating the causal effect of X 233

- on Y despite the presence of unobserved socio-economic variables, using the back-234
- door adjustment formula (equation 15) [36]. Prevalence of diabetes was chosen as a 235
- surrogate for obesity because it is easier to quantify precisely (through data on the 236
- sale of diabetes medication). 237

4.4 Statistical model 238

The statistical analysis was carried out within a Bayesian framework. An overview of 239 the model is featured in Figure 5, where the equations of the model are referenced next 240 to the variables. In the remainder of this section, prior distributions are not always



Fig. 5: Overview of the model. The blue and red rectangles represent the exposure and outcome of the main analysis, respectively. The numbers indicate the equations associated with the variables (see the Model section).

IFR: Infection fatality rate.

IHR: Infection hospitalization rate.

241

248

explicitly written. If so, the latter are uniform. Age groups are indexed by the letter 242 i (i = 0 for individuals aged 20 to 59, and i = 1 for individuals aged over 60). The 243 departments are indexed by the letter j, ranging from 1 to 95. 244

For an age group i and a department j, the participants without a positive RT-PCR 245

nor missing data on department contributed to the estimation of seroprevalence $s_{i,j}$, 246 considering $N_{i,j}$ the number of these participants, and $y_{i,j}$ the number of positive 247 serological tests:

$$y_{i,j} \sim \mathcal{B}(N_{i,j}, s_{i,j}) \tag{1}$$

Seroprevalence at the scale of metropolitan France (sero_{France}) was obtained by post-249 stratification from $s_{i,j}$ and $pop_{i,j}$, the size of the population corresponding to this 250

group: 251

$$\operatorname{ero}_{\operatorname{France}} = \frac{\sum_{i,j} \operatorname{pop}_{i,j} \times s_{i,j}}{\sum_{i,j} \operatorname{pop}_{i,j}}$$
(2)

Seroprevalence estimates from other surveys were incorporated using beta distribu-252 tions: 253

$$sero_{France} \sim Beta(101, 1948) \quad (implies a 95\% \text{ CI of } 4.02\text{-}5.89\% \text{ [15]}) \\ sero_{France} \sim Beta(1147, 17212) \quad (implies a 95\% \text{ CI of } 5.90\text{-}6.60\% \text{ [29]}) \quad (3)$$

For an age group i and a department j, incidence (cumulated over the first semester) 254

was denoted $p_{i,j}$. Seroprevalence $s_{i,j}$ was linked to incidence $p_{i,j}$ and to the sensitivity 255

(Se) and specificity (Sp) of the serological test: 256

$$s_{i,j} = Se \times p_{i,j} + (1 - Sp) \times (1 - p_{i,j})$$
(4)

Prior distributions for sensitivity and specificity originated from [30]: 257

S

The participants with a positive RT-PCR contributed to the likelihood of sensitivity. 258

With $N_{\rm se}$ and $y_{\rm se}$ the number of total and positive (respectively) serological tests in 259 this group, 260

$$y_{\rm se} \sim \mathcal{B}(N_{\rm se}, \mathrm{Se})$$
 (6)

Incidence $p_{i,j}$ was modeled on the logit scale. As it was suggested that older persons 261 could be under-represented in the population of infected persons at the early stages 262 of the epidemic [19], every department had a unique log-odds ratio for age over 60 263 (β_i) , possibly influenced by its intercept α_i (logit of incidence in the 20-59 in the 264 department j) through a linear regression with intercept μ_{age} , slope b_{age} and standard 265 deviation σ_{age} (hierarchical modeling, β_j is a random effect): 266

logit
$$p_{i,j} = \alpha_j + \beta_j \times i$$

random slope (7)
 $\beta_i \sim N(\mu_{age} + \alpha_j \times b_{age}, \sigma_{age})$

The α_i departmental intercepts entailed spatial auto-correlation through an ICAR 267 (intrinsic conditional auto-regressive) component ϕ_j (as described and implemented in 268 this reference [37]), associated with an overall intercept μ_{α} and a scale parameter σ_{ϕ} 269 representing the amount of spatial correlation: 270

$$\alpha_{j} = \mu_{\alpha} + \phi_{j} \times \sigma_{\phi}$$

$$\sigma_{\phi} \sim \text{Exponential}(1) \quad (\text{weakly informative prior on } \sigma_{\phi})$$
(8)

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The proportion $\operatorname{age}_{\operatorname{infected},j}$ of persons over 60 among those infected in a department j was reconstructed from $p_{i,j}$ and from $\operatorname{age}_{\operatorname{pop},j} = \frac{\operatorname{pop}_{1,j}}{\operatorname{pop}_{1,j} + \operatorname{pop}_{0,j}}$ (the proportion of persons above 60 in the population of the department j):

$$\operatorname{age}_{\operatorname{infected},j} = \frac{p_{1,j} \times \operatorname{age}_{\operatorname{pop},j}}{p_{1,j} \times \operatorname{age}_{\operatorname{pop},j} + p_{0,j} \times (1 - \operatorname{age}_{\operatorname{pop},j})}$$
(9)

For a given incidence in the persons under 60, we estimated an expected proportion of persons over 60 among those infected for a department with the same age structure as metropolitan France. This expected proportion was reconstructed from the coefficients μ_{age} , β_{age} , and σ_{age} (equation 7), according to a procedure described in the Supplementary information file ("Computation of expectations" section). This analysis aimed to illustrate the dependence between incidence in people under 60 and incidence in those over 60, and its possible consequences for IFR.

The K participants with a positive RT-PCR and no missing data concerning the department contributed directly to incidence. With IS_k being the infection status of the participant k (IS_k is always equal to 1 in this positive RT-PCR group),

$$IS_k \sim Bern(p_{i,j}) \qquad (For \ k = 1, \dots, K) \tag{10}$$

Departmental incidence inc_j was obtained by post-stratification from $p_{i,j}$ and $pop_{i,j}$:

$$\operatorname{inc}_{j} = \frac{\sum_{i} \operatorname{pop}_{i,j} \times p_{i,j}}{\sum_{i} \operatorname{pop}_{j}}$$
(11)

For a department j, the counts of deaths (D_j) and hospitalizations (H_j) of the first semester were modeled with Poisson regressions:

$$D_{j} \sim \text{Poisson}(\text{IFR}_{j} \times \text{inc}_{j} \times \sum_{i} \text{pop}_{i,j})$$

$$\mathbf{H}_{j} \sim \text{Poisson}(\text{IHR}_{j} \times \text{inc}_{j} \times \sum_{i} \text{pop}_{i,j})$$

²⁸⁷ Departmental IFRs and IHRs were modeled as logistic functions of linear predictors ²⁸⁸ $g_{\text{IFR}}(j)$ and $g_{\text{IHR}}(j)$, ranging respectively from 0% to 5% and from 0% to 10%:

$$IFR_{j} = \frac{0.05}{1 + e^{-g_{IFR}(j)}} \quad (\text{logistic function ranging from 0\% to 5\%})$$

$$IHR_{j} = \frac{0.10}{1 + e^{-g_{IHR}(j)}} \quad (\text{logistic function ranging from 0\% to 10\%})$$
(13)

These linear predictors included a departmental random intercept, a slope representing the role of incidence, and coefficients associated with the covariates (prevalence of

diabetes, number of intensive care beds per inhabitant and proportion of the popula-291 tion over 60). With diab_j, age_{pop,j}, and beds_j being the covariates for the department 292 j,293

$$g_{\text{IFR}}(j) = \mu_{\text{IFR}_j} + \text{inc}_j \times c_p + \text{diab}_j \times c_{\text{diab}} + \text{age}_{\text{pop},j} \times c_{\text{age}} + \text{beds}_j \times c_{\text{beds}}$$

$$g_{\text{IHR}}(j) = \mu_{\text{IHR}_j} + \text{inc}_j \times d_p + \text{diab}_j \times d_{\text{diab}} + \text{age}_{\text{pop},j} \times d_{\text{age}} + \text{beds}_j \times d_{\text{beds}}$$

$$g_{\text{IHR}}(j) = \mu_{\text{IHR}_j} + \text{inc}_j \times d_p + \text{diab}_j \times d_{\text{diab}} + \text{age}_{\text{pop},j} \times d_{\text{age}} + \text{beds}_j \times d_{\text{beds}}$$

$$m_{\text{role of incidence}}$$

$$\mu_{\text{IFR}_j} \sim N(m_{\text{IFR}}, \sigma_{\text{IFR}})$$

$$\mu_{\text{IHR}_j} \sim N(m_{\text{IFR}}, \sigma_{\text{IFR}})$$

$$\sigma_{\text{IFR}} \sim \text{Exponential(1) (weakly informative prior on \sigma_{\text{IFR}})$$

$$\sigma_{\text{IHR}} \sim \text{Exponential(1) (weakly informative prior on \sigma_{\text{IHR}})$$

Because the covariates satisfy the back-door criterion, the adjusted IFR can be equated 294 to the causal effect of incidence on IFR using the back-door adjustment formula [36]. 295 P(IFR|do(inc = x)) denotes this causal effect, which is the distribution of departmen-296 tal IFRs if incidence was artificially set to the value x without any other modification. 297 With z_j denoting the vector of covariates for department j, and because the distri-298 bution of these covariates in the French departments is known $(P(z_j) = \frac{1}{95}$ for all 299 j),300 diusted IFB given incide

$$\frac{P(\text{IFR}|do(\text{inc} = x))}{\text{causal effect of incidence } x \text{ on IFR}} = \sum_{j=1}^{95} P(\text{IFR}|x, z_j) \times P(z_j)$$

$$= \frac{1}{95} \sum_{j=1}^{95} P(\text{IFR}|x, z_j)$$
(15)

The coefficients of equation 14 were used to compute E[IFR|do(inc = x)], as described 301 in the supplementary information file ("Reconstruction of expectations" section). The 302 target of this study was the average causal effect of an incidence shift from 3% to 9%: 303

$$E[IFR|do(inc = 9\%)] - E[IFR|do(inc = 3\%)]$$
(16)

This average causal effect corresponds to the expected difference in IFR when arti-304 ficially setting incidence to 9% versus 3% in a department of metropolitan France 305 (without changing anything else than incidence). The same procedure was applied to 306 estimate the average causal effect of this incidence shift on IHR. 307

4.5 Algorithm and software 308

The data management was done using R version 4.3.1, and the modeling was per-309 formed with Stan (R package cmdstanr version 0.5.3), which implements Hamiltonian 310 Monte Carlo (HMC) [38, 39]. The models for the random coefficients (β_j , μ_{IFR_j} and 311

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

 μ_{IFR_j}) employed non-centered parameterizations to improve HMC convergence [40]. The Monte Carlo sampling consisted of 8 chains of 2,000 iterations each (including 1,000 warm up iterations). Trace plots, \hat{R} statistics and effective Monte Carlo sample sizes provided by Stan were used to assess convergence. Posterior predictive checks are provided in the Supplementary information file. The model's code (in Stan) is provided in the Supplementary information file and in a GitHub repository (https://github.com/bglemain/does-hospital-overload).

³¹⁹ 4.6 Ethical approval and consent to participate

Ethical approval and written or electronic informed consent were obtained from each participant before enrollment in the original cohort. The SAPRIS-SERO study was approved by the Sud-Mediterranée III ethics committee (approval 20.04.22.74247) and electronic informed consent was obtained from all participants for dried blood spot testing. The study was registered (#NCT04392388). All methods were performed in accordance with the relevant guidelines and regulations.

- Supplementary information. The Supplementary information file attached with this article contains:
- A flowchart
- The number of serological samples for each department and age group
- The exhaustive list of departmental estimates (incidence, IFR, IHR) and characteristics (covariates, population size, counts of deaths and hospitalizations)
- Complementary results (univariate analysis, role of the confounders)
- The procedure used to compute expectations after a logistic transformation
- Posterior predictive checks
- The Stan code

Acknowledgments. The authors warmly thank all the volunteers of the Constances, E3N-E4N, and NutriNet-Santé cohorts. We thank the staff of the Constances, E3N-E4N and NutriNet-Santé cohorts that have worked with dedication and engagement to collect and manage the data used for this study and to ensure continuing communication with the cohort participants. We thank the CEPH-Biobank staff for their adaptability and the quality of their work. We thank all the members of the SAPRIS-SERO study group (see Supplementary information file).

343 Declarations

• Funding: This study ANR (Agence Nationale de la Recherche, #ANR-20-COVI-344 000. #ANR-10-COHO-06), Fondation pour la Recherche Médicale (#20RR052-345 00), Inserm (Institut National de la Santé et de la Recherche Médicale, #C20-26). 346 The sponsor and funders facilitated data acquisition but did not participate 347 in the study design, analysis, interpretation or drafting. Cohorts funding The 348 CONSTANCES Cohort Study is supported by the Caisse Nationale d'Assurance 349 Maladie (CNAM), the French Ministry of Health, the Ministry of Research, the 350 Institut national de la santé et de la recherche médicale. CONSTANCES benefits 351

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

from a grant from the French National Research Agency [Grant Number ANR-352 11-INBS-0002] and is also partly funded by MSD, AstraZeneca, Lundbeck and 353 L'Oreal. The E3N-E4N cohort is supported by the following institutions: Min-354 istère de l'Enseignement Supérieur, de la Recherche et de l'Innovation, INSERM, 355 University Paris-Saclay, Gustave Roussy, the MGEN, and the French League 356 Against Cancer. The NutriNet-Santé study is supported by the following public 357 institutions: Ministère de la Santé, Santé Publique France, Institut National de la 358 Santé et de la Recherche Médicale (INSERM), Institut National de la Recherche 359 Agronomique (INRAE), Conservatoire National des Arts et Métiers (CNAM) 360 and Sorbonne Paris Nord. The CEPH-Biobank is supported by the Ministère de 361 l'Enseignement Supérieur, de la Recherche et de l'Innovation. 362

- Competing interests: The authors declare no competing interests.
- Ethics approval: Ethical approval and written or electronic informed consent were obtained from each participant before enrolment in the original cohort. The SAPRIS-SERO study was approved by the Sud-Mediterranée III ethics committee (approval #20.04.22.74247)
- Consent to participate: An electronic informed consent was obtained from all participants for DBS testing
- Consent for publication: Participants can not be identified on the basis of this article
- Availability of data and materials: In regard to data availability, data from the 372 ٠ study are protected under the protection of health data regulation set by the 373 French National Commission on Informatics and Liberty (Commission Nationale 374 de l'Informatique et des Libertés, CNIL). The data can be made available upon 375 reasonable request to F.C. (fabrice.carrat@iplesp.upmc.fr), after a consultation 376 with the steering committee of the SAPRIS-SERO study. The French law forbids 377 us to provide free access to SAPRIS-SERO data; access could however be given 378 by the steering committee after legal verification of the use of the data. Please, 379 feel free to come back to us should you have any additional question. 380
- Code availability: The code Stan for the model is provided in Supplementary information file

Authors' contributions: F.C., N.L., C.A., W.G., P.M, and B.G. conceived and designed the study. B.G. implemented the model and wrote the manuscript. All the authors reviewed and edited the manuscript.

³⁶⁶ Consortium (SAPRIS-SERO study group)

Fabrice Carrat^{1,2}, Pierre-Yves Ancel¹¹, Marie-Aline Charles¹¹, Gianluca Severi^{7,8},
Mathilde Touvier⁹, Marie Zins^{5,6}, Sofiane Kab⁶, Adeline Renuy⁶, Stephane Le-Got⁶,
Celine Ribet⁶, Mireille Pellicer⁶, Emmanuel Wiernik⁶, Marcel Goldberg⁶, Fanny
Artaud⁷, Pascale Gerbouin-Rérolle⁷, Mélody Enguix⁷, Camille Laplanche⁷, Roselyn Gomes-Rima⁷, Lyan Hoang⁷, Emmanuelle Correia⁷, Alpha Amadou Barry⁷,
Nadège Senina⁷, Julien Allegre⁹, Fabien Szabo de Edelenyi⁹, Nathalie DruesnePecollo⁹, Younes Esseddik⁹, Serge Hercberg⁹, Mélanie Deschasaux⁹, Marie-Aline
Charles¹¹, Valérie Benhammou¹², Anass Ritmi¹³, Laetitia Marchand¹³, Cecile Zaros¹³,

- Elodie Lordmi¹³, Adriana Candea¹³, Sophie de Visme¹³, Thierry Simeon¹³, Xavier Thierry¹³, Bertrand Geay¹³, Marie-Noelle Dufourg¹³, Karen Milcent¹³, Delphine 396 Rahib¹⁴, Nathalie Lydie¹⁴, Clovis Lusivika-Nzinga¹, Gregory Pannetier¹, Nathanael 397 Lapidus^{1,2}, Isabelle Goderel¹, Céline Dorival¹, Jérôme Nicol¹, Olivier Robineau¹, 398 Cindy Lai¹⁵, Liza Belhadji¹⁵, Hélène Esperou¹⁵, Sandrine Couffin-Cadiergues¹⁵, 399 Jean-Marie Gagliolo¹⁶, Hélène Blanché¹⁰, Jean-Marc Sébaoun¹⁰, Jean-Christophe 400 Beaudoin¹⁰, Laetitia Gressin¹⁰, Valérie Morel¹⁰, Ouissam Ouili¹⁰, Jean-François 401 Deleuze¹⁰, Laetitia Ninove⁴, Stéphane Priet⁴, Paola Mariela Saba Villarroel⁴, Toscane 402 Fourié⁴, Souand Mohamed Ali⁴, Abdenour Amroun⁴, Morgan Seston⁴, Nazli Ayhan⁴, 403 Boris Pastorino⁴, Xavier de Lamballerie⁴. 404
- ¹Sorbonne Université, Inserm, Institut Pierre-Louis d'épidémiologie et de santé 405 publique, Paris, France 406
- ²Département de santé publique, Hôpital Saint-Antoine, AP-HP.Sorbonne université, 407 Paris, France 408
- ⁴Unité des Virus Émergents, UVE, Aix Marseille Univ, IRD 190, INSERM 1207, IHU 409
- Méditerranée Infection, Marseille, France 410
- ⁵Paris University, Paris, France 411
- ⁶Université Paris-Saclay, Université de Paris, UVSQ, Inserm UMS 11, Villejuif, France 412
- ⁷CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, 413 France 414
- ⁸Department of Statistics, Computer Science and Applications, University of Florence, 415 Italy 416
- ⁹Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epi-417
- demiology Research Team (EREN), Epidemiology and Statistics Research Center 418 University of Paris (CRESS), Bobigny, France 419
- ¹⁰Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), 420 **CEPH-Biobank**, Paris, France 421
- ¹¹Centre for Research in Epidemiology and Statistics (CRESS), Inserm, INRAE, Uni-422
- versité de Paris, Paris, France 423
- ¹²EPIPAGE-2 Joint Unit, Paris, France 424
- ¹³ELFE Joint Unit, Paris, France 425
- ¹⁴Santé Publique France, Paris, France 426
- ¹⁵Inserm, Paris, France 427
- ¹⁶Aviesan, Inserm, Paris, France 428

References 429

- [1] Candel, F. J. et al. Temporary hospitals in times of the COVID pandemic. An 430 example and a practical view. Rev. Esp. Quimioter. 34, 280 (2021). 431
- [2] Lefrant, J.-Y. et al. A national healthcare response to intensive care bed require-432
- ments during the COVID-19 outbreak in France. Anaesth Crit Care Pain Med 433
- **39**, 709–715 (2020). 434

- [3] Jimenez, J. V. et al. Outcomes in Temporary ICUs Versus Conventional ICUs: 435 An Observational Cohort of Mechanically Ventilated Patients With COVID-19-436
- Induced Acute Respiratory Distress Syndrome. Crit Care Explor 4, e0668 (2022). 437
- [4] Souris, M. & Gonzalez, J.-P. COVID-19: Spatial analysis of hospital case-fatality 438 rate in France. PLoS One 15, e0243606 (2020). 439
- [5] Zappella, N. et al. Temporary ICUs during the COVID-19 pandemic first wave: 440 Description of the cohort at a French centre. BMC Anesthesiol 22, 310 (2022). 441
- [6] Janke, A. T. et al. Analysis of Hospital Resource Availability and COVID-19 442 Mortality Across the United States. J Hosp Med 16, 211–214 (2021). 443
- [7] Sen-Crowe, B., Sutherland, M., McKenney, M. & Elkbuli, A. A Closer Look Into 444 Global Hospital Beds Capacity and Resource Shortages During the COVID-19 445 Pandemic. J Surg Res 260, 56–63 (2021). 446
- [8] Dudel, C. et al. Monitoring trends and differences in COVID-19 case-fatality rates 447 using decomposition methods: Contributions of age structure and age-specific 448 fatality. PLoS One 15, e0238904 (2020). 449
- [9] Lau, H. et al. Evaluating the massive underreporting and undertesting of COVID-450 19 cases in multiple global epicenters. Pulmonology 27, 110–115 (2021). 451
- [10] Borgdorff, M. W. New Measurable Indicator for Tuberculosis Case Detection. 452 Emerg. Infect. Dis. 10, 1523 (2004). 453
- [11] COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio 454 by age, time, and geography during the pre-vaccine era: A systematic analysis. 455 Lancet **399**, 1469–1488 (2022). 456
- [12] O'Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-457 2. Nature **590**, 140–145 (2021). 458
- [13] Pezzullo, A. M., Axfors, C., Contopoulos-Ioannidis, D. G., Apostolatos, A. & 459 Ioannidis, J. P. A. Age-stratified infection fatality rate of COVID-19 in the non-460 elderly population. *Environ Res* **216**, 114655 (2023). 461
- [14] Ioannidis, J. P. A. Infection fatality rate of COVID-19 inferred from seropreva-462 lence data. Bull World Health Organ 99, 19–33F (2021). 463
- [15] Le Vu, S. et al. Prevalence of SARS-CoV-2 antibodies in France: Results from 464 nationwide serological surveillance. Nat Commun 12, 3025 (2021). 465
- Carrat, F. et al. Antibody status and cumulative incidence of SARS-CoV-2 infec-16 466 tion among adults in three regions of France following the first lockdown and 467 associated risk factors: A multicohort study. Int J Epidemiol 50, 1458–1472 468 (2021).469

- [17] COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Inves-470 tigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults 471
- with COVID-19: A prospective cohort study. Intensive Care Med 47, 60-73 472 (2021).473
- [18] Brown, P. A. Country-level predictors of COVID-19 mortality. Sci Rep 13, 9263 474 (2023).475
- [19] Tran Kiem, C. et al. SARS-CoV-2 transmission across age groups in France and 476 implications for control. Nat Commun 12, 6895 (2021). 477
- [20] Glemain, B. et al. Estimating SARS-CoV-2 infection probabilities with serological 478 data and a Bayesian mixture model. Sci Rep 14, 9503 (2024). 479
- [21] Tennant, P. W. G. et al. Use of directed acyclic graphs (DAGs) to identify 480 confounders in applied health research: Review and recommendations. Int J 481 Epidemiol 50, 620–632 (2021). 482
- [22] Carrat, F. et al. Incidence and risk factors of COVID-19-like symptoms in the 483 French general population during the lockdown period: A multi-cohort study. 484 BMC Infect Dis 21, 169 (2021). 485
- [23] Carrat, F. et al. Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity 486 profiles after the first wave of the pandemic in France. Infection 50, 257–262 487 (2022).488
- [24] Hercherg, S. et al. The Nutrinet-Santé Study: A web-based prospective study 489 on the relationship between nutrition and health and determinants of dietary 490 patterns and nutritional status. BMC Public Health 10, 242 (2010). 491
- [25] Zins, M. & Goldberg, M. The French CONSTANCES population-based cohort: 492 Design, inclusion and follow-up. Eur J Epidemiol 30, 1317–1328 (2015). 493
- [26] Clavel-Chapelon, F. & E3N Study Group. Cohort Profile: The French E3N Cohort 494 Study. Int J Epidemiol 44, 801–809 (2015). 495
- [27] Morley, G. L. et al. Sensitive Detection of SARS-CoV-2-Specific Antibodies in 496 Dried Blood Spot Samples. Emerg Infect Dis 26, 2970–2973 (2020). 497
- [28] Zava, T. T. & Zava, D. T. Validation of dried blood spot sample modifications to 498 two commercially available COVID-19 IgG antibody immunoassays. *Bioanalysis* 499 **13**, 13–28 (2021). 500
- Warszawski, J. et al. Trends in social exposure to SARS-Cov-2 in France. Evidence 501 from the national socio-epidemiological cohort-EPICOV. PLoS One 17, e0267725 502 (2022).503

- [30] Otter, A. D. et al. Implementation and Extended Evaluation of the Euroim-504 mun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's 505 COVID-19 Public Health Response. Microbiol Spectr 10, e0228921 (2022). 506
- population [31] Populations légales 2020 Recensement de la 507 Régions, départements, arrondissements, cantons communes. et 508 https://www.insee.fr/fr/statistiques/6683031?sommaire=6683037. 509
- [32] Données hospitalières relatives à l'épidémie de COVID-19 (SIVIC). 510 https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-511 lepidemie-de-covid-19/. 512
- [33] Covid-19 Inserm-CépiDc. https://opendata.idf.inserm.fr/cepidc/covid-19/. 513
- [34] Géodes Santé publique France. https://geodes.santepubliquefrance.fr/#c=home. 514
- [35] La Statistique annuelle des établissements (SAE) | Direction de la recherche, 515 des études, de l'évaluation et des statistiques. https://drees.solidarites-516 sante.gouv.fr/sources-outils-et-enquetes/00-la-statistique-annuelle-des-517 etablissements-sae. 518
- [36] Pearl, J. Causal Diagrams for Empirical Research. *Biometrika* 82, 669–688 519 (1995).520
- [37] Morris, M. et al. Bayesian hierarchical spatial models: Implementing the Besag 521 York Mollié model in stan. Spat Spatiotemporal Epidemiol 31, 100301 (2019). 522
- [38] R Core Team. R: A Language and Environment for Statistical Computing. R 523 Foundation for Statistical Computing, Vienna, Austria (2023). URL https:// 524 www.R-project.org/. 525
- [39] Carpenter, B. et al. Stan: A Probabilistic Programming Language. J Stat Softw 526 76, 1 (2017). 527
- [40] Papaspiliopoulos, O. & Roberts, G. Non-Centered Parameterisations for Hier-528 archical Models and Data Augmentation. Bayesian Statistics 7, 307–326 529 (2003).530